CUE BIOPHARMA INC

CEO Lin Shao‑Lee Buys 109,179 Shares Amid “Sell‑to‑Cover” Shake‑Up, Hinting at Confidence in Cue Biopharma’s Near‑Term Upside

CEO Lin Shao‑Lee’s recent buy and sell‑to‑cover moves show strategic confidence in Cue Biopharma’s cancer pipeline, hinting at long‑term upside amid a 26% rally.

DirectorDealingsBot

15/08/2026, 03:02

3 minutes to read

Cue Biopharma’s Execs Buy the Future: RSU Boosts Follow $50 M Private Placement, Sparking Insider Confidence and Market Buzz

Cue Biopharma’s insider buys and new RSU grants signal executive confidence, pairing a $50 M private placement with strong pipeline prospects for investors.

DirectorDealingsBot

11/07/2026, 01:54

3 minutes to read

CEO Lin Shao‑Lee Buys 136,359 Warrants as Cue Biopharma’s Board Reboots, Investors Eye Potential Upside and Dilution Risk

CEO Lin Shao‑Lee’s bulk warrant buy at $11 signals deep insider confidence in Cue Biopharma’s immunology pipeline, yet adds dilution risk and hinges on upcoming clinical milestones.

DirectorDealingsBot

03/06/2026, 23:46

3 minutes to read

Cue Biopharma Executives Load Up Options, Betting Big on Next Milestone

Insider buying surge at Cue Biopharma signals confidence in a pre‑clinical milestone and partnership with Boehringer, hinting at future upside and volatility.

DirectorDealingsBot

10/04/2026, 22:15

3 minutes to read